E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Septic shock |
Choque septico |
|
E.1.1.1 | Medical condition in easily understood language |
Sepsis with severe circulatory impairment |
Sepsis con severo deterioro circulatorio |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040050 |
E.1.2 | Term | Sepsis NOS |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of the CLASSIC trial is to assess benefits and harms of IV fluid restriction vs. standard of care on patient-important outcome measures in adult ICU patients with septic shock. |
El objetivo del ensayo clínico CLASSIC es evaluar los beneficios y los daños de la restricción de líquidos por vía intravenosa frente al estándar de atención en pacientes adultos con UCI con shock séptico. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
No aplicable |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All the following criteria must be fulfilled: - Aged 18 years or above - Admitted to the ICU or plan to be admitted to the ICU regardless of trial participation - Septic shock defined according to the Sepsis-3 criteria: o Suspected or confirmed site of infection or positive blood culture AND o Ongoing infusion of vasopressor/inotrope agent to maintain a mean arterial blood pressure of 65 mmHg or above AND o Lactate of 2 mmol/L or above in any plasma sample performed within the last 3-hours - Have received at least 1 L of IV fluid (crystalloids, colloids or blood products) in the last 24-hours prior to screening. |
Todos los siguientes criterios deben cumplirse: - De 18 años o más - Admitido en la UCI o plan para ser admitido en la UCI independientemente de la participación en el ensayo - Choque séptico definido según los criterios de Sepsis-3: o Sitio de infección sospechoso o confirmado o hemocultivo positivo e o Infusión continua de agente vasopresor / inotropo para mantener una presión arterial media de 65 mmHg o superior Y o Lactato de 2 mmol / L o más en cualquier muestra de plasma realizada en las últimas 3 horas - Han recibido al menos 1 L de líquido IV (cristaloides, coloides o productos sanguíneos) en las últimas 24 horas antes del examen. |
|
E.4 | Principal exclusion criteria |
We will exclude patients who fulfil any of the following criteria: - Septic shock for more than 12 hours at the time of screening because we want to include patients early in their course - Life-threatening bleeding as these patients need specific fluid/blood product strategies - Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy - Known pregnancy. - Consent not obtainable as per the model approved for the specific site. |
Excluiremos pacientes que cumplan con alguno de los siguientes criterios: - Shock séptico durante más de 12 horas en el momento de la detección porque queremos incluir a los pacientes al principio de su ciclo - Sangrado que pone en peligro la vida ya que estos pacientes necesitan estrategias específicas de fluidos / productos sanguíneos - Lesión aguda por quemaduras de más del 10% del área de la superficie del cuerpo ya que estos pacientes necesitan una estrategia de fluidos específica - Embarazo conocido. - Consentimiento no obtenible según el modelo aprobado para el sitio específico. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
All-cause mortality at day 90 after randomisation |
Todas las causas de mortalidad hasta el día 90 después de la aleatorización |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
day 90 after randomisation |
90 días después de la aleatorización |
|
E.5.2 | Secondary end point(s) |
- Number of participants with one or more serious adverse events (SAEs) in the ICU defined as ischaemic events (cerebral, cardiac, intestinal or limb ischaemia) or as a new episode of severe acute kidney injury (modified KDIGO3) - Number of participants with one or more serious adverse reactions (SARs) to IV crystalloids in the ICU. - Days alive at day 90 without life support (vasopressor / inotropic support, invasive mechanical ventilation or renal replacement therapy) - Days alive and out of hospital at day 90 - All-cause mortality at 1-year after randomisation - HRQoL 1-year after randomisation measured using the EuroQoL (EQ)-5D-5L and EQ-VAS scores. Participants who have died will be assigned the lowest possible scores - Cognitive function 1-year after randomisation as assessed by the Montreal Cognitive Assessment (MoCa) score |
- Número de participantes con uno o más eventos adversos graves (AAG) en la UCI definidos como eventos isquémicos (isquemia cerebral, cardíaca, de las extremidades) o como un nuevo episodio de lesión renal aguda grave (KDIGO3 modificado) - Número de participantes con una o más reacciones adversas graves (SAR) a cristaloides IV en la UCI. - Días vivos al día 90 sin soporte vital (soporte vasopresor / inotrópico, ventilación mecánica invasiva o terapia de reemplazo renal) - Días vivos y fuera del hospital el día 90 - Mortalidad por todas las causas al año después de la aleatorización - HRQoL 1 año después de la aleatorización medida con los puntajes EuroQoL (EQ) -5D-5L y EQ-VAS. A los participantes que hayan fallecido se les asignarán los puntajes más bajos posibles - Función cognitiva 1 año después de la asignación al azar según lo evaluado por el puntaje de Evaluación Cognitiva de Montreal (MoCa) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
during ICU admission, day 90 after randomisation or 1 year after randomisation |
Durante la admisión a la UCI, el día 90 después de la aleatorización o 1 año después de la aleatorización |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
fluid resuscitation reflecting standard care |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when number of randomised patients reach 1554 |
El ensayo finalizará cuando el número de pacientes asignados al azar llegue a 1554 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |